Hypertension Accelerates Liver Disease Progression in MASLD- AJG Feb.26
Introduction
Metabolically–dysfunction–associated steatotic liver disease (MASLD) frequently coexists with hypertension, yet blood pressure has traditionally been viewed mainly through a cardiovascular lens. Whether hypertension directly influences liver disease progression and long-term hepatic outcomes has remained uncertain.
This large, multicohort study addresses that gap by asking a simple but important question:
Does hypertension independently worsen outcomes and fibrosis progression in MASLD?
What the investigators did:
The authors analysed three large, complementary cohorts:
A population-based cohort to assess long-term clinical outcomes (death, cardiovascular events, liver-related events).
A noninvasive elastography cohort to evaluate liver stiffness progression over time.
A paired liver biopsy cohort to directly measure histologic fibrosis progression.
By combining population data, noninvasive markers, and histology, the study provides a uniquely robust picture of disease evolution.
Key findings clinicians should understand
- Hypertension independently worsens long-term outcomes
Patients with MASLD and hypertension experienced more adverse clinical events over time—not only cardiovascular events, but also liver-related complications and mortality.
- Hypertension accelerates liver disease progression
Across two independent measures of disease activity:
Liver stiffness increased faster, and
Fibrosis progressed more frequently
in patients with hypertension compared with those without.
- This is not just association—it’s consistent across methods
The relationship between hypertension and MASLD progression was seen:
in population-level data,
with noninvasive fibrosis assessment, and
on paired histologic evaluation.
This consistency strongly supports a true biological link, not just confounding.
Why this matters clinically
Hypertension is modifiable
Unlike many genetic or metabolic drivers, blood pressure is treatable—making it a practical intervention point.
MASLD care must be multidisciplinary
These findings emphasize that optimal MASLD management requires:
hepatology,
cardiology,
and primary care alignment.
Risk stratification should change
Patients with MASLD and hypertension represent a higher-risk subgroup who may benefit from:
closer fibrosis monitoring,
earlier use of noninvasive tools (e.g., elastography), and
more aggressive cardiometabolic risk control.
Pathophysiologic perspective:
Hypertension may contribute to liver injury through:
endothelial dysfunction,
altered hepatic microcirculation,
systemic inflammation, and
shared metabolic pathways with insulin resistance.
These mechanisms provide biologic plausibility for the observed acceleration of fibrosis.
Bottom-line takeaway from GastroAGI
Hypertension is not just a cardiovascular comorbidity in MASLD—it is a key, modifiable driver of liver disease progression and adverse outcomes. Blood pressure control should be a core component of MASLD management.
One-line GastroAGI takeaway
In MASLD, controlling blood pressure may help protect the liver as much as the heart.
